Loading...
Statins clearly confer substantial benefit in people with established cardiovascular (CV) disease (secondary prevention); however, the magnitude of benefit in people without CV disease (primary prevention) is less clear. In this meta-analysis of 10 randomized controlled trials that involved 70,000 patients, investigators assessed the effects of statins in people without CV disease but with CV risk factors.
Participants (mean age, 63; 34% women) were followed for an average of 4.1 years. Compared with participants in the statin group, significantly more participants in the control group died (5.1% vs. 5.7%; odds ratio, 0.88), had major adverse coronary events (4.1% vs. 5.4%; OR, 0.70), or had major adverse cerebrovascular events (1.9% vs. 2.3…